InnovAge Revenue Jumps 11% in Fiscal Q4

InnovAge (NASDAQ:INNV) reported robust Q4 FY2025 results, with revenue up 11.0% to $221.4 million and non-GAAP EBITDA surging 117.3% to $11.3 million, driven by strong participant enrollment and improved operational efficiency. While significant one-time charges, including a $10.1 million litigation accrual and $13.6 million in asset impairments, resulted in an unchanged net loss per share of $(0.01), underlying profitability and core business momentum were strong, exceeding guidance. The company projects continued growth for FY2026, with revenue expected to reach $900-950 million and adjusted EBITDA $56-65 million, indicating a positive outlook despite ongoing regulatory and balance sheet considerations.

Analysis

InnovAge (INNV) reported strong underlying operational performance for Q4 FY2025, which was obscured by significant one-time charges. Revenue grew a solid 11.0% year-over-year to $221.4 million, driven primarily by a 10.3% increase in participant enrollment, demonstrating sustained demand for its PACE model. More significantly, non-GAAP adjusted EBITDA surged 117.3% to $11.3 million, nearly doubling the associated margin to 5.1% from 2.6% in the prior-year quarter. This margin expansion reflects successful execution on strategic initiatives, including insourcing services and improving center-level contribution, which rose 12.8%. However, the headline net loss per share remained flat at $(0.01) due to a $10.1 million litigation accrual and a $13.6 million asset impairment charge. While the balance sheet shows an increase in cash and a modest decrease in long-term debt, a rise in total liabilities warrants monitoring. The company's forward guidance for FY2026 is robust, projecting 5-11% revenue growth and a substantial 62-89% increase in adjusted EBITDA, signaling management's confidence in continued business transformation and margin improvement.

Key Decisions for Investors

• Investors should look beyond the headline net loss, which was distorted by significant one-time charges, and focus on the strong underlying operational improvements, particularly the 117% growth in non-GAAP EBITDA and expanding margins.
• The bullish FY2026 guidance, projecting adjusted EBITDA growth of 62-89%, serves as a primary positive catalyst; however, execution on converting this to GAAP profitability will be a critical performance indicator.
• Key risks to monitor include ongoing regulatory scrutiny from CMS, the frequency of future one-time charges, and the management of the balance sheet, specifically the increase in total liabilities against cash reserves.